Len is a gamechanging drug to prevent HIV infections, priced by Gilead at $28,200. Limited drug is available at cost to ...

Unlike daily PrEP, the injection is administered once every six months, offering continuous protection over that period.

The U.S. Food and Drug Administration on April 21, 2026, approved Merck’s Idvynso, a once-daily combination pill for HIV ...

Data from ARTISTRY trials demonstrated that switching to a single-tablet regimen of bictegravir and lenacapavir is ...

Researchers found that certain immune cells, genes, and the drug metformin may help keep HIV dormant after treatment stops, ...

Participation in state AIDS Drug Assistance Programs was associated with improved HIV treatment outcomes and high rates of viral suppression.

The newly approved HIV drug Idvynso will also help Merck diversify as loss of exclusivity looms over its top-selling product, ...

The U.S. Food and Drug Administration (FDA) recently approved a groundbreaking new option for preventing HIV, the virus that causes AIDS. The injectable drug lenacapavir was approved in June and is ...

When the Trump administration began dismantling US foreign aid in January 2025, many global health experts feared that the ...

Prism Health North Texas, a community health center, participated in clinical trials for Merck's new HIV treatment, Idvynso.

Tens of thousands of Americans are at risk of losing access to HIV treatment as nearly 20 states tighten eligibility rules for AIDS Drug Assistance Programs, known as ADAPs.

The US Food and Drug Administration (FDA) has added more detailed definitions for treatment-naïve and treatment-experienced HIV patients and provides recommendations for designing switch trials, ...